Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scientists at Mumbai, India-based drug maker Elder Pharmaceuticals have come up with a novel drug delivery system (NDDS) for a nutraceutical formulation called Coenzyme Q(10) [CO Q10].
Subscribe to our email newsletter
So far COQ10 products were available mostly as soft-gel capsules or as tablets. Elder said that its R&D centre worked extensively on the development of a chewable form of CO Q10- offering optimum dose of 100 mg per tablet – making it more palatable & acceptable to patient population thereby expanding the market for the same.
Launched through the ethical route under the brand name of Ecozyme, the nutraceutical helps build immunity and is effective in fighting Cardiovascular diseases, neurogenerative diseases particularly Parkinson’s & Alzheimer’s, Migraine, hypertension and diabetes.
Elder is targeting sales of about INR300m by 2012. The company has a tie-up with M/s Gnosis Labs, Italy for the purchase of the API.
Elder Pharma already has a major presence in the nutraceutical market with a range of products like Eldervit ZC, Nephrocaps, IMBRAN from Daiwa of Japan, Elmecob & Phytomega from Enzymotec of Israel. This has facilitated Elder to capture a sizeable share of the nutraceutical market segment.
Thus, addition of Ecozyme to the product portfolio of Elder Pharma is expected lead to a consolidation of its presence in this segment.
Says Alok Saxena, director of Elder, said: “When we expanded our R&D centre by adding about 50 scientists over the last one year, our primary goal was to concentrate on NDDS rather than molecule research. The technology in developing the chewable form of COQ10 is a unique technology & Elder is in the process of filing for worldwide patents also.”